Market Place
Sourcing Support
Dynavax To Present At Evercore Healthcare Conference
20 Nov 2025 //
PR NEWSWIRE BIO
Dynavax To Present Q3 2025 Financial Results And Host Conference
22 Oct 2025 //
PR NEWSWIRE
Dynavax to Attend 2025 Wells Fargo Healthcare Conference
27 Aug 2025 //
PR NEWSWIRE
Dynavax to Present Q2 2025 Financial Results on August 7
29 Jul 2025 //
PR NEWSWIRE
Dynavax Stockholders Elect All Director Nominees at 2025 Meeting
11 Jun 2025 //
PR NEWSWIRE
Glass Lewis Backs Deep Track`s Board Change at Dynavax
04 Jun 2025 //
BUSINESSWIRE
Dynavax to Present at William Blair`s Growth Stock Conference
28 May 2025 //
PR NEWSWIRE
Dynavax`s feud with investor heats up ahead of annual meeting
12 May 2025 //
FIERCE BIOTECH
Dynavax reports Q1 2025 results and new pipeline programs
06 May 2025 //
PR NEWSWIRE
Dynavax Emphasizes Superior Board Leadership for Value Creation
29 Apr 2025 //
PR NEWSWIRE
Dynavax to Report Q1 2025 Results, Host Call on May 6
22 Apr 2025 //
PR NEWSWIRE
Dynavax to Participate in Upcoming Investor Conferences
25 Feb 2025 //
PR NEWSWIRE
Dynavax Reports Q4 & FY24 Results, Provides FY25 Financial Guidance
20 Feb 2025 //
PR NEWSWIRE
Dynavax to Report Q4 & Full Year 2024 Financial Results
06 Feb 2025 //
PR NEWSWIRE
Dynavax Advances Board Refreshment Program
27 Jan 2025 //
PR NEWSWIRE
Dynavax Reports Preliminary Q4, Full-Year 2024 Financial Highlights
13 Jan 2025 //
PR NEWSWIRE
Dynavax to Present at 7th Annual Evercore HealthCONx Conference
26 Nov 2024 //
PR NEWSWIRE
Dynavax Announces $100 Million Accelerated Share Repurchase Program
11 Nov 2024 //
PR NEWSWIRE
Dynavax Announces $200 Million Share Repurchase Program
07 Nov 2024 //
PR NEWSWIRE
Dynavax To Report Q3 Financial Results 2024 Results On Nov 7
24 Oct 2024 //
PR NEWSWIRE
US FDA declines expanded use of Dynavax`s hepatitis B insufficient data
15 May 2024 //
REUTERS
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
20 Nov 2023 //
PR NEWSWIRE
Dynavax Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
PRESS RELEASE
Dynavax to Report First Quarter 2023 Financial Results and Host Conference
18 Apr 2023 //
PR NEWSWIRE
Dynavax to Present at Two Upcoming Investor Conferences
09 Nov 2022 //
PRNEWSWIRE
Dynavax to Report Third Quarter Financial Results
20 Oct 2022 //
PRNEWSWIRE
Dynavax to Present at H.C. Wainwright 3rd Annual Hepatitis B Virus Conference
14 Oct 2022 //
PRNEWSWIRE
Dynavax - First Participant Dosed in Evaluating an Adjuvanted Plague Vaccine
12 Sep 2022 //
PRNEWSWIRE
Dynavax to Present at the H.C. Wainwright Annual Global Investment Conference
08 Sep 2022 //
PRNEWSWIRE
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
25 May 2022 //
PRNEWSWIRE
Why Dynavax Stock Won on a Losing Monday for the Market
16 May 2022 //
FOOL
Dynavax to Present at the H.C. Wainwright Global Investment Conference
16 May 2022 //
PRNEWSWIRE
Dynavax Reports First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Dynavax Reports Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
PRNEWSWIRE
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
23 Feb 2022 //
PRNEWSWIRE
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2022 //
PRNEWSWIRE
Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference
18 Nov 2021 //
PRNEWSWIRE
Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
21 Oct 2021 //
PRNEWSWIRE
Dynavax, US DOD collaborate to develop recombinant plague vaccine
05 Oct 2021 //
PHARMABIZ
Dynavax, US DOD collaborate to develop recombinant plague vaccine
05 Oct 2021 //
PHARMABIZ
Dynavax and U.S. Department of Defense Announce Collaboration
04 Oct 2021 //
PRNEWSWIRE
Dynavax to Present at Upcoming Investment Conferences
27 Sep 2021 //
PRNEWSWIRE
Matinas, Dynavax top weekly healthcare gainers; InnovAge, BeyondSpring trail
24 Sep 2021 //
SEEKINGALPHA
Dynavax in clover on Covid-19 vaccine data
23 Sep 2021 //
EVALUATE
Dynavax Provides Update on its COVID-19 Collaboration with Valneva
13 Sep 2021 //
PRNEWSWIRE
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Sep 2021 //
PRNEWSWIRE
Dynavax underperforms as insider selling picks up
20 Aug 2021 //
SEEKINGALPFA
Biological E Announce Commercial Supply Agreement for Dynavax`s CpG 1018
07 Jul 2021 //
PR NEWSWIRE
Biological E Announce Commercial Supply Agreement for Dynavax`s CpG 1018
07 Jul 2021 //
PR NEWSWIRE
Dynavax to supply its CpG 1018 adjuvant for Biological E`s COVID-19 Vaccine
06 Jul 2021 //
ECONOMIC TIMES
Clover, Dynavax Ink Commercial Supply Agreement of Dynavax`s CpG 1018 Adjuvant
30 Jun 2021 //
PR NEWSWIRE
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Jun 2021 //
PR NEWSWIRE
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax
27 May 2021 //
GLOBENEWSWIRE
Dynavax Announces Agreement with Bavarian for Commercialization of HEPLISAV B
27 May 2021 //
PRNEWSWIRE
HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 (ACVR)
27 Apr 2021 //
PRNEWSWIRE
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®
19 Feb 2021 //
PRNEWSWIRE
Dynavax and Serum of India Announce First Participant Dosed in a Pha1 Trial
04 Feb 2021 //
PRNNEWSWIRE
Dynavax announces UK Government exercise option to order additional 40 m VLA2001
02 Feb 2021 //
PHARMABIZ
Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant
01 Feb 2021 //
PRNEWSWIRE
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial
01 Feb 2021 //
PRNEWSWIRE
